Document:

exhibit_10-17.htm

Exhibit 10.17

  

[Translation from Hebrew]

 

State of Israel

Ministry of Trade and Industry

Industrial Research and Development Administration

Office of Chief Scientist

 

Jerusalem

Letter of Approval Number: 38481

(Fiscal regulation: 38020101)

Group: 13

  

To

Pluristem Ltd.

POB – 15105

Haifa 31905

 

Letter of Approval

 

	  	
1.

	
We hereby inform you that the research committee, by virtue of its authority according to Article 17 of the Law for the Encouragement of Research and Development in the Industry, 5744-1984 (hereinafter: the “R&D Law”), has resolved in its meeting on 01/05/2007 to approve the program as submitted by you on 27/02/2007, which subject matter is:

 

	  	
a.

	
Subject of approved program: Development of PLX-1 MSC 3D cultures to improve absorption of umbilical cord blood transfusion with BMT.

 

	  	
b.

	
Performing the approved program: Pluristem Ltd.

 

	  	  	
Registration Number: 513371666

(hereinafter - the “Approved Program”)

 

	  	
2.

	

a. The research and development expenses approved for the performance of the approved program will be in an amount of up to: NIS6,665,926.

 

In words: Six million, six hundred and sixty-five thousand, nine hundred twenty six NIS.

 

b. The rate of grant approved is 50% of the development expenses (addition with respect to a national priority zone A/ line of confrontation), which is up to an amount of NIS 3,332,963.

 

In words: Three million, three hundred thirty-two thousand, nine hundred and sixty-three NIS.

 

	  	
3.

	
The approval is conditioned upon fulfillment of the provisions of the law, regulations, rules and procedures promulgated thereunder and subject to the following terms:

 

	  	
a.

	
The approved program will be performed as detailed in your request within a period of 12 months – from 01/3/2007 and until 29/2/2008 (hereinafter: the “Performance Period”).

 

	  	
b.

	
(1) You must inform the Office of the Chief Scientist about every change in the control of the recipient of the grant in the company’s shares and/or in one of the following controlling means: (a) the right to vote in the company’s general meetings; (b) the right to appoint directors in the company; (c) the right to participate in the company’s profits.

 

(2) Transferring any percentage of the controlling means stated in subsection (1) to a non-Israeli resident or to a foreign company, which make the non-Israeli resident or foreign company an interested party as defined in the Securities Law, 1968, requires notification to Office of the Chief Scientist and a written undertaking of the non-Israeli resident or the foreign company to the R&D Law.

 

The letter of approval shall be signed in the form existing in the office of the Chief Scientist and in the website of the Ministry of Industry, Trade and Employment.

 

  

  

  

 

	  	
c.

	
Additional terms:

 

Royalties shall be paid on Company’s income from treatments based on PLX-1.

 

	  	
d.

	
See the appendix in the matter of intellectual property.

 

	  	
e.

	
In the event of pledging the company’s assets to an Israeli bank against credit, the company must ensure that the pledge shall be subject to the R&D Law.

 

	  	
f.

	
If the plan is connected to an agreement with an academic institution or an academic implementation company, the company must ensure that the agreement is subject to the provisions of the R&D Law.

 

	  	
Sincerely,

	  	  
	  	
/s/ Dr. Eli Ofer

	  	
Dr. Eli Ofer

The Chief Scientistexhibit_10-18.htm

Exhibit 10.18

  

[Translation from Hebrew]

 

State of Israel

Ministry of Trade and Industry

Industrial Research and Development Administration

Office of Chief Scientist

 

Jerusalem

Letter of Approval Number: 40100

(Fiscal regulation: 38020101)

Group: 13

  

To

Pluristem Ltd.

POB – 15105

Haifa 31905

 

Letter of Approval

 

	  	
1.

	
We hereby inform you that the research committee, by virtue of its authority according to Article 17 of the Law for the Encouragement of Research and Development in the Industry, 5744-1984 (hereinafter: the “R&D Law”), has resolved in its meeting on 25/11/2008 to approve the program as submitted by you on 31/03/2008, which subject matter is:

 

	  	
a.

	
Subject of approved program: PLX for implant absorption and PAD treatment.

 

	  	
b.

	
Performing the approved program: Pluristem Ltd.

 

	  	  	
Registration Number: 513371666

(hereinafter - the “Approved Program”)

 

	  	
2.

	

a. The research and development expenses approved for the performance of the approved program will be in an amount of up to: NIS12,408,241.

 

In words: Twelve million, four hundred and eight thousand, two hundred forty-one NIS.

 

b. The rate of grant approved is 50% of the development expenses (addition with respect to a national priority zone A/ line of confrontation), which is up to an amount of NIS 6,204,121.

 

In words: Six million, two hundred and four thousand, one hundred and twenty NIS.

 

	  	
3.

	
The approval is conditioned upon fulfillment of the provisions of the law, regulations, rules and procedures promulgated thereunder and subject to the following terms:

 

	  	
a.

	
The approved program will be performed as detailed in your request within a period of 12 months – from 01/3/2008 and until 28/2/2009 (hereinafter: the “Performance Period”).

 

	  	
b.

	
(1) You must inform the Office of the Chief Scientist about every change in the control of the recipient of the grant in the company’s shares and/or in one of the following controlling means: (a) the right to vote in the company’s general meetings; (b) the right to appoint directors in the company; (c) the right to participate in the company’s profits.

 

(2) Transferring any percentage of the controlling means stated in subsection (1) to a non-Israeli resident or to a foreign company, which make the non-Israeli resident or foreign company an interested party as defined in the Securities Law, 1968, requires notification to Office of the Chief Scientist and a written undertaking of the non-Israeli resident or the foreign company to the R&D Law.

 

The letter of approval shall be signed in the form existing in the office of the Chief Scientist and in the website of the Ministry of Industry, Trade and Employment.

 

  

  

  

 

	  	
c.

	
Additional terms:

 

Payment upon performance.

 

Royalties shall be paid on Company’s income.

 

	  	
d.

	
See the appendix in the matter of intellectual property.

 

	  	
e.

	
In the event of pledging the company’s assets to an Israeli bank against credit, the company must ensure that the pledge shall be subject to the R&D Law.

 

	  	
f.

	
If the plan is connected to an agreement with an academic institution or an academic implementation company, the company must ensure that the agreement is subject to the provisions of the R&D Law.

 

	  	
Sincerely,

	  	  
	  	
/s/ Dr. Eli Ofer

	  	
Dr. Eli Ofer

The Chief Scientistexhibit_10-19.htm

Exhibit 10.19

  

[Translation from Hebrew]

 

State of Israel

Ministry of Trade and Industry

Industrial Research and Development Administration

Office of Chief Scientist

 

Jerusalem

Letter of Approval Number: 41702

(Fiscal regulation: 38020101)

Group: 13

  

To

Pluristem Ltd.

POB – 15105

Haifa 31905

 

Letter of Approval

 

	  	
1.

	
We hereby inform you that the research committee, by virtue of its authority according to Article 17 of the Law for the Encouragement of Research and Development in the Industry, 5744-1984 (hereinafter: the “R&D Law”), has resolved in its meeting on 26/05/2009 to approve the program as submitted by you on 08/03/2009, which subject matter is:

 

	  	
a.

	
Subject of approved program: Treatment with mesenchyme placental cells grown in a culture.

 

	  	
b.

	
Performing the approved program: Pluristem Ltd.

 

	  	  	
Registration Number: 513371666

(hereinafter - the “Approved Program”)

 

	  	
2.

	

a. The research and development expenses approved for the performance of the approved program will be in an amount of up to: NIS14,659,687.

 

In words: Fourteen million, six hundred fifty-nine thousand six hundred eighty-seven NIS.

 

b. The rate of grant approved is 50% of the development expenses (addition with respect to a national priority zone A/ line of confrontation), which is up to an amount of NIS 7,329,844.

 

In words: Seven million, three hundred and twenty-nine thousand, eight hundred and forty-four NIS.

 

	  	
3.

	
The approval is conditioned upon fulfillment of the provisions of the law, regulations, rules and procedures promulgated thereunder and subject to the following terms:

 

	  	
a.

	
The approved program will be performed as detailed in your request within a period of 12 months – from 01/3/2009 and until 28/2/2010 (hereinafter: the “Performance Period”).

 

	  	
b.

	
(1) You must inform the Office of the Chief Scientist about every change in the control of the recipient of the grant in the company’s shares and/or in one of the following controlling means: (a) the right to vote in the company’s general meetings; (b) the right to appoint directors in the company; (c) the right to participate in the company’s profits.

 

(2) Transferring any percentage of the controlling means stated in subsection (1) to a non-Israeli resident or to a foreign company, which make the non-Israeli resident or foreign company an interested party as defined in the Securities Law, 1968, requires notification to Office of the Chief Scientist and a written undertaking of the non-Israeli resident or the foreign company to the R&D Law.

 

The letter of approval shall be signed in the form existing in the office of the Chief Scientist and in the website of the Ministry of Industry, Trade and Employment.

 

  

  

  

 

	  	
c.

	
Additional terms:

 

Royalties shall be paid on Company’s income.

 

	  	
d.

	
See the appendix in the matter of intellectual property.

 

	  	
e.

	
In the event of pledging the company’s assets to an Israeli bank against credit, the company must ensure that the pledge shall be subject to the R&D Law.

 

	  	
f.

	
If the plan is connected to an agreement with an academic institution or an academic implementation company, the company must ensure that the agreement is subject to the provisions of the R&D Law.

 

	  	
Sincerely,

	  	  
	  	
/s/ Dr. Eli Ofer

	  	
Dr. Eli Ofer

The Chief Scientist

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00235-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00235-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00235-of-00352.parquet"}]]